CLEO
20.5.2019 09:02:06 CEST | Business Wire | Press release
Gartner’s Application Architecture, Development & Integration (AADI) Summit returns to London to provide strategies for solving the pervasive challenges of orchestrating workflows between external B2B and application ecosystems with internal business systems. Cleo , the global leader in ecosystem integration solutions, will be exhibiting in Booth S3 to demonstrate how successful organisations leverage its “outside-in” approach to create seamless end-to-end workflows and help optimize business processes.
The Gartner AADI 2019 event , taking place 20-21 May at Park Plaza Westminster, is designed to empower IT and business professionals in transforming their application architecture, agile development, and integration strategies. The event’s focus on application strategies and data processes in the era of the cloud highlights the need for better ways to execute application integration, an inescapable challenge in today’s business landscape.
According to the 2019 State of Ecosystem and Integration Application Report , integration is a constant battle for organisations, with 25% of companies struggling to integrate new applications with legacy systems. All told, unreliable partner and application integrations are costing companies approximately $500,000 every year. Cleo will showcase at the Gartner AADI summit how to solve these challenges using an innovative approach that integrates the dynamic ecosystem of people, partners, customers, systems, applications, and things and supports the critical data flows driving revenue.
About Cleo Integration Cloud
Today’s data exchange requirements often are dictated by the partners, suppliers, customers, vendors, and all their respective technologies comprising a modern business ecosystem, and it demands a change in how we view traditional integration patterns. Conference-goers visiting the Cleo booth will learn hands-on about the business benefits of technology embracing this fresh POV – integration that prioritises external customer and trading partner data processes and integrates them seamlessly into internal workflows – via the Cleo Integration Cloud platform.
Cleo’s flagship offering is a single, hybrid integration platform enabling organisations to connect, transform, integrate, orchestrate, and analyse end-to-end application, B2B, cloud, and data integrations for improved visibility across global business ecosystems. Cleo Integration Cloud facilitates the heavy lifting of integration while also providing dynamic dashboards to empower technical and business users to make better decisions, create stronger relationships with trading partners, and accelerate growth as data requirements evolve. The result is end-to-end transparency throughout internal networks and external business ecosystems, which enables organisations to maximise the value of their application investments.
Agenda Highlights
The opening keynote for this year’s Gartner AADI summit is titled, “Optimize, Integrate and Transform to Achieve Your Digital Future” and features Gartner’s Elizabeth Golluscio, managing vice president, Keith Guttridge, senior director analyst, and Mark O'Neill, VP analyst. The speakers will explore how organisations pursuing digital transformation must apply modern digital application and integration strategies to advance those initiatives.
The agenda also features a number of topics spanning cloud integration challenges, strategic application trends, modernising core systems, postmodern ERP integration, and how smart application integration delivers next-generation customer experiences. The nature of the 2019 agenda further emphasizes the value an ecosystem-driven approach can have in designing application integration processes that support innovation, align with business goals, and deliver competitive advantage.
“Organisations are at a tipping point in how they integrate all the ERPs, CRMs, e-commerce, and other business-critical applications they deploy almost daily,” said Cleo CMO Tushar Patel . “It’s individual departments and lines of business that are driving technology investment, rather than the traditional IT teams, and it requires a change in how they approach application integration. Today’s integration technology should give companies a path to optimising their core business processes while solving external B2B and internal application integration challenges simultaneously.”
Patel adds: “The companies treating application and B2B interactions as separate, disparate business processes are leaving value on the table and will get left behind.”
Come see Cleo at Booth S3 for a Cleo-themed cocktail – an “Ecosystem Integration Elixir” – and to learn how Cleo customers are achieving success every day with Cleo Integration Cloud. To learn more about Cleo, and how Cleo Integration Cloud can help your business, visit our website – www.cleo.com .
For more insights on what to expect at the event, read the blog titled, “Ecosystem Integration & Value Beyond the Gartner AADI London Agenda.”
About Gartner AADI 2019
The Gartner Application Architecture, Development & Integration Summit 2019 is designed for application leaders to learn about crafting leading-edge applications, architectures and strategies leveraging microservices, DevOps and artificial intelligence, and more. Attendees can gain intensive learning and actionable insight as they plan to drive growth through digital business transformation.
About Cleo
Cleo is an ecosystem integration software company focused on business outcomes, ensuring each customer’s potential is realized by delivering solutions that make it easy to discover and create value through the movement and integration of enterprise data. Cleo gives customers a strategic, “outside-in” visibility into the critical end-to-end business flows happening across their ecosystems of partners and customers, marketplaces, and internal cloud and on-premise applications. Our solutions empower teams to drive business agility, accelerate onboarding, facilitate modernisation of key business processes, and capture new revenue streams by reimagining and remastering their digital ecosystem through robust application, B2B, and data integration technologies. For more information, visit www.cleo.com or call +1.815.282.7695.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190520005142/en/
Contact:
Media Contacts Matt Torman Senior Manager, Marketing Communications Cleo +1.815.282.7610
Drew Smith Senior Account Manager 10Fold Communications (for Cleo) +1.415.800.5374
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
